Catalyst

Slingshot members are tracking this event:

Genfit Phase 2 study testing ELAFIBRANOR (GFT505) in primary biliary cirrhosis (PBC) expecting to enroll first patient in Q2 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GNFTF Community voting in process
GNFT.PA Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Elafibranor, Gft505, Phase 2, Primary Biliary Cirrhosis